Day: March 27, 2023

BEIJING, March 27, 2023 (GLOBE NEWSWIRE) — NaaS Technology Inc. (“NaaS” or the “Company”) (Nasdaq: NAAS), one of the largest and fastest growing electric vehicle charging service providers in China, today reported its adjusted unaudited financial results for the quarter and six months ended June 30, 2022. The Company has adjusted its unaudited financial results for the quarter and six months ended June 30, 2022 originally reported on August 22, 2022 to correct the presentation of revenues to be consistent with the Company’s recognition and measurement policy for each class of revenues and reflect other adjustments that the Company found necessary or appropriate, including mainly the following:revising the presentation of gross revenues, incentive to end-users, and net revenues. revising the measurement policy for revenue...

Annual Revenue of $202.8 million, up 21%YOYGross profit of $63.5 million, up 68%YOYGross margin of 31.3%, up 870 bps YOYDirect sales of $37.4 million, up 69% YOYSubscription revenue of $14.5 million, up 54% YOY LOS ANGELES, March 27, 2023 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (NASDAQ:EGLX; TSX:EGLX), an integrated gaming entertainment company, today announced financial results for the fiscal year ended December 31, 2022. “Our 2022 financial and operating results continue to demonstrate that Enthusiast Gaming is on the path to achieving sustained profitability in 2023. The Company achieved record performance in each of its main KPI’s, including revenue, gross profit, gross margin, direct sales, and subscriptions, despite challenging macroeconomic conditions that impacted programmatic...

– Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b) in the second half of 2023 – – Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical evaluation as lead, next-generation CTLA-4 program – – Continued progress in strategic alliances including first clinical candidate milestone in Probody T-Cell Bispecific collaboration with Astellas and initiation of Regeneron and Moderna collaborations – – CytomX to evaluate future development opportunities for CX-2029 (conditionally activated CD71-directed ADC) and pursue additional strategies for CD71 targeting following AbbVie’s decision not to advance the...

Fiscal year 2022 revenue up 80%, generating $11.5 million of cash from operations Expects continued momentum and growth in fiscal 2023 Provides revenue, deliveries and Adjusted EBITDA guidance for 2023 CHICAGO, March 27, 2023 (GLOBE NEWSWIRE) — FreightCar America, Inc. (NASDAQ: RAIL) (“FreightCar America” or the “Company”), a diversified manufacturer of railroad freight cars, today reported results for the fourth quarter and full year ended December 31, 2022. Fiscal Year 2022 HighlightsRevenues of $364.8 million, up 79.6% year-over-year, on deliveries of 3,184 railcars, up 83.9% year-over-year Gross margin of 7.1% with gross profit of $25.8 million, compared to gross margin of 5.6% with gross profit of $11.5 million in fiscal year 2021 Net loss of ($38.8) million, or ($1.56) per share and adjusted net loss of ($23.5) million,...

PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023. The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures. About NANOBIOTIX: Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment...

Fourth quarter revenue grew 37% year-over-year Forian exits cannabis industry with sale of BioTrack for $30 million NEWTOWN, PA, March 27, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter and year ended December 31, 2022. “I am proud of the team’s fourth quarter results,” said Max Wygod, Forian’s Chairman and Chief Executive Officer. “By leveraging our vast and innovative healthcare information assets together with our expertise in data management and analytics, we have executed on our growth strategy and outperformed our 2022 revenue outlook. Additionally, the steps we are taking to operate in a financially prudent manner have sequentially improved...

– Announces key appointments in oncology R&D and business development functions – Cash and cash equivalents of $283 million expected to provide runway into 2026 FOSTER CITY, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity today reported financial results for the fourth quarter and full year ended December 31, 2022 and corporate updates. “As announced in our release earlier this month, 2023 promises to be another transformative year for Terns as we make meaningful strides to advance our pipeline of medicines to address serious unmet needs. In addition...

Strategic Focus on Achieving 99% 2-Qubit Median Fidelity on 84 Qubit Chip BERKELEY, Calif., March 27, 2023 (GLOBE NEWSWIRE) —  Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter of 2022Total revenues for the three months ended December 31, 2022 were $6.1 million, compared to $1.8 million in the same period of 2021. Total operating expenses for the three months ended December 31, 2022 were $32.0 million, compared to $12.2 million in the same period of 2021. Operating loss for the three months ended December 31, 2022 was $26.7 million, compared to $11.1 million in the same period of 2021. Net loss for the three months ended December 31, 2022 was $22.9...

HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023 Completion of $25 million preferred equity financing provides sufficient cash to fund operations into the second half of 2024, beyond key data milestones Five posters on multiple programs to be presented at AACR 2023 in April SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. “Harpoon is well positioned to reach 2023 key milestones on our HPN217 and HPN328 clinical studies with a solid balance sheet extending the cash...